Domtar Corp (USA) (UFS) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $0.35 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $0.39. The company posted revenue of $1287.00 million in the period, compared to analysts expectations of $1276.33 million. The company’s revenue was down -2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS.
Many Wall Street Analysts have commented on Domtar Corp (USA). Domtar Corp (USA) was Downgraded by BofA/Merrill to ” Underperform” on Apr 6, 2016.
Domtar Corp (USA) opened for trading at $41.21 and hit $41.81 on the upside on Wednesday, eventually ending the session at $41.77, with a gain of 1.63% or 0.67 points. The heightened volatility saw the trading volume jump to 9,41,890 shares. Company has a market cap of $2,617 M.
In a different news, on Sep 9, 2015, Michael Fagan (President, Personal Care) sold 4,500 shares at $40.00 per share price. According to the SEC, on Feb 27, 2015, John David Williams (President and CEO) sold 21,426 shares at $44.15 per share price.
Domtar Corporation designs manufactures markets and distributes a range of fiber-based products including communication papers specialty and packaging papers and absorbent hygiene products. The Company operates in two business segments: Pulp and Paper and Personal Care. The Company’s Pulp and Paper segment is engaged in the design manufacturing marketing and distribution of communication papers specialty and packaging papers as well as softwood fluff and hardwood market pulp. The Company’s Personal Care segment is involved in the manufacturing marketing and distribution of absorbent hygiene products. The Company is an integrated marketer and manufacturer of uncoated freesheet paper in North America for a range of customers including merchants retail outlets stationers printers publishers converters and end-users. It is also a marketer and producer of a broad line of incontinence care products.